Edition:
United States

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

2.83USD
4:00pm EDT
Change (% chg)

$-0.09 (-3.08%)
Prev Close
$2.92
Open
$2.85
Day's High
$2.85
Day's Low
$2.70
Volume
56,078
Avg. Vol
177,468
52-wk High
$11.00
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Evoke Pharma Q4 loss per share $0.12
Wednesday, 15 Mar 2017 04:05pm EDT 

Evoke Pharma Inc : Evoke pharma reports fourth quarter and full year 2016 results . Q4 loss per share $0.12 .Q4 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma announces pricing of public offering
Thursday, 16 Feb 2017 08:46am EST 

Evoke Pharma Inc : Evoke Pharma announces pricing of public offering of common stock .Says public offering of 2.41 million common shares priced at $2.90 per share.  Full Article

Evoke Pharma Q2 loss per share $0.41
Monday, 15 Aug 2016 05:00pm EDT 

Evoke Pharma Inc : Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.41.  Full Article

Evoke Pharma Q2 shr loss $0.41
Monday, 15 Aug 2016 04:31pm EDT 

Evoke Pharma Inc : Evoke pharma reports second quarter 2016 results . Q2 shr loss $0.41 . Q2 shr view $-0.43 -- thomson reuters i/b/e/s .Evoke Pharma says "we will continue to work with fda to pursue a path to approval of gimoti".  Full Article

Evoke Pharma announces $10 million registered direct offering
Friday, 29 Jul 2016 03:15pm EDT 

Evoke Pharma Inc : Evoke Pharma announces $10 million registered direct offering priced at-the-market .Says will issue common stock at a purchase price of $3.0825 per share.  Full Article

Empery Asset Management LP reports 6.65 pct passive stake in Evoke Pharma
Friday, 29 Jul 2016 07:09am EDT 

Evoke Pharma Inc :Empery Asset Management LP reports 6.65 percent passive stake in Evoke Pharma Inc as of July 19 - Sec filing.  Full Article

Evoke Pharma provides update on proposed name for lead drug
Tuesday, 26 Jul 2016 08:30am EDT 

Evoke Pharma: Receives conditional FDA acceptance of proposed brand name for Evk-001 .Request for proprietary name review for gimoti will be included if and when evoke submits a nda for product candidate.  Full Article

Evoke pharma determined it was out of compliance with some financial covenants under Square 1 Bank agreement
Wednesday, 20 Jul 2016 08:14am EDT 

Evoke Pharma : On July 19 Co determined that it was out of compliance with some financial covenants under loan and security agreement with Square 1 bank .Pursuant to credit facility, square 1 agreed to make term loans available to company in a principal amount of up to $4.5 million - SEC filing.  Full Article

Evoke Pharma completes phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis
Wednesday, 1 Jun 2016 08:30am EDT 

Evoke Pharma Inc : Completes Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis . Will be ready to move forward with new drug application in near term, should we receive positive data from this trial .Expects to report top-line Phase 3 study results early in Q3 of 2016.  Full Article

Evoke Pharma Q1 loss per share $0.45
Wednesday, 11 May 2016 04:05pm EDT 

Evoke Pharma Inc : Evoke pharma reports first quarter 2016 results . Q1 loss per share $0.45 .Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Evoke Pharma Q4 loss per share $0.12

* Evoke pharma reports fourth quarter and full year 2016 results